Photo by quinterocamilaa from unsplash
PURPOSE To review the data regarding a new antipsychotic, cariprazine. CONCLUSIONS Cariprazine is a dopamine D3, D2 partial agonist, with greater affinity to D3. It has been examined for schizophrenia,… Click to show full abstract
PURPOSE To review the data regarding a new antipsychotic, cariprazine. CONCLUSIONS Cariprazine is a dopamine D3, D2 partial agonist, with greater affinity to D3. It has been examined for schizophrenia, bipolar mania, bipolar depression, and unipolar depression. It has demonstrated efficacy in schizophrenia and mania, and has recently been approved by the U.S. Food and Drug Administration. However, it has a more inconsistent effect in depression, both unipolar and bipolar. Adverse effects include extrapyramidal symptoms, akathisia, and gastrointestinal distress. PRACTICE IMPLICATIONS Cariprazine will be a promising addition in the treatment of patients with acute mania and schizophrenia.
Journal Title: Perspectives in Psychiatric Care
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!